Assenagon Asset Management Acquires Stake in Halozyme Therapeutics

The institutional investor adds 72,085 shares of the biopharmaceutical company to its portfolio.

Mar. 29, 2026 at 7:20am

Got story updates? Submit your updates here. ›

Assenagon Asset Management S.A. acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, according to the company's most recent filing with the Securities & Exchange Commission. The institutional investor acquired 72,085 shares of the biopharmaceutical company's stock, valued at approximately $4,851,000.

Why it matters

This investment by Assenagon Asset Management, a major European asset manager, signals confidence in Halozyme Therapeutics' growth potential and drug pipeline. As a biopharmaceutical company focused on novel drug delivery technologies, Halozyme's performance is closely watched by investors in the healthcare and biotech sectors.

The details

Assenagon Asset Management now owns 0.06% of Halozyme Therapeutics' outstanding shares. The investment comes as other large institutional investors, such as DLD Asset Management and Arrowstreet Capital, have also increased their stakes in the company recently. Halozyme Therapeutics is known for its ENHANZE® technology, which enables subcutaneous administration of biologic therapies.

  • Assenagon Asset Management acquired the Halozyme Therapeutics shares during the 4th quarter of 2025.

The players

Assenagon Asset Management S.A.

A major European asset management firm that has acquired a new position in shares of Halozyme Therapeutics.

Halozyme Therapeutics, Inc.

A biopharmaceutical company headquartered in San Diego, California that specializes in the development and commercialization of novel drug-delivery technologies.

Got photos? Submit your photos here. ›

The takeaway

This investment by Assenagon Asset Management underscores the growing institutional interest in Halozyme Therapeutics and its innovative drug delivery platform. As the company continues to advance its pipeline and commercialize its technologies, it will be closely watched by investors seeking exposure to the dynamic healthcare and biotech sectors.